USP9X and ovarian cancer: Encouragingly, USP9X inhibitor conferred the ovarian cancer cells higher sensitivity to chemotherapeutic agents, and reduced the IC50 significantly (CDDP: IC50: 5.882 μM vs. 1.278 μM for CAOV3; 5.568 μM vs. 2.107 μM for ID8; PTX: IC50: 5.058 nM vs. 3.026 nM for CAOV3, 5.887 nM vs. 2.663 nM for ID8).